ZBIO Key Statistics, Chart & Performance
The current stock price of ZBIO is 36.58 USD. In the past month the price decreased by -1.32%. In the past year, price increased by 272.13%.
ZBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.31 | 406.04B | ||
| AMGN | AMGEN INC | 15.03 | 176.99B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.14 | 115.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.92 | 52.48B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 31.74B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.8 | 21.37B | ||
| INCY | INCYTE CORP | 15.41 | 19.42B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About ZBIO
Company Profile
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company is headquartered in Waltham, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2024-09-13. The firm's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The firm is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
Company Info
ZENAS BIOPHARMA INC
1000 Winter St, Suite 1200
Waltham MASSACHUSETTS US
Employees: 130
Phone: 18572712954
ZENAS BIOPHARMA INC / ZBIO FAQ
What does ZBIO do?
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company is headquartered in Waltham, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2024-09-13. The firm's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The firm is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
Can you provide the latest stock price for ZENAS BIOPHARMA INC?
The current stock price of ZBIO is 36.58 USD. The price decreased by -6.33% in the last trading session.
What is the dividend status of ZENAS BIOPHARMA INC?
ZBIO does not pay a dividend.
What is the ChartMill rating of ZENAS BIOPHARMA INC stock?
ZBIO has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does ZENAS BIOPHARMA INC have?
ZENAS BIOPHARMA INC (ZBIO) currently has 130 employees.
What is the market capitalization of ZBIO stock?
ZENAS BIOPHARMA INC (ZBIO) has a market capitalization of 1.96B USD. This makes ZBIO a Small Cap stock.
What is the next earnings date for ZBIO stock?
ZENAS BIOPHARMA INC (ZBIO) will report earnings on 2026-03-09.
ZBIO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ZBIO. When comparing the yearly performance of all stocks, ZBIO is one of the better performing stocks in the market, outperforming 99.14% of all stocks.
ZBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZBIO. The financial health of ZBIO is average, but there are quite some concerns on its profitability.
ZBIO Financial Highlights
Over the last trailing twelve months ZBIO reported a non-GAAP Earnings per Share(EPS) of -7.26. The EPS decreased by -296.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.97% | ||
| ROE | -96.68% | ||
| Debt/Equity | 0.37 |
ZBIO Forecast & Estimates
14 analysts have analysed ZBIO and the average price target is 48.71 USD. This implies a price increase of 33.15% is expected in the next year compared to the current price of 36.58.